Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

CartiHeal's Agili-C™ Implant Enhances In-vitro Osteogenic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells

KFAR SABA, Israel, May 30, 2019 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of osteochondral and chondral defects, announced today the publication of anin-vitro study demonstrating that the Agili-C™ implant enhances osteogenic differentiation of human...

2019-05-30 20:00 1993

Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809

HONG KONG, May 29, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by t...

2019-05-29 18:00 4938

After $7.1 Billion Sale Of Frutarom, Ori Yehudai To Join The Sade Group As Active Chairman and Investor

NESS ZIONA, Israel, May 27, 2019 /PRNewswire/ -- Ori Yehudai: "I took a company worth$3 million and sold it to IFF at $7.1 billion in 2018. In my opinion, the success of our cannabis company will be to build an industrial pharmaceutical company with the strictest standards, we had two such plants...

2019-05-27 20:05 2563

After $7.1 Billion Sale Of Frutarom, Ori Yehudai To Join The Sade Group As Active Chairman and Investor

Sihuan Pharm Becomes the First Chinese Company that was Granted Approval for "Non-PVC Solid-Liquid Double Chamber Bag for Ceftazidime/Sodium Chloride Injection"

HONG KONG, May 27, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Group"), the largest cardio-cerebral vascular ("CCV") drug manufacturer in China's prescription drug market, announced the "non-PVC solid-liquid double chamber bag for ...

2019-05-27 17:08 5066

111 to Collaborate with MSH to Build Internet Pharmaceutical and Healthcare Service Closed-loop System

SHANGHAI, May 24, 2019 /PRNewswire/ -- Following 111, Inc.'s (NASDAQ: YI) ("111" or the "Company") strategic partnership with Manulife-Sinochem last year, the Company has reached another milestone. OnMay 24, 111 and MSH, a world leader in the design and management of international healthcare solu...

2019-05-24 22:45 8423

Phebra establishes new subsidiary in Canada and announces marketing approval for its IV Arsenic Trioxide Solution

SYDNEY, May 23, 2019 /PRNewswire/ -- Australian pharmaceutical firm Phebra (the 'Company') has continued its international business expansion with the opening of its subsidiary inMontreal, Canada. The new entity, Phebra Canada, will be headed byTony Romagnino, Vice President of Phebra's current N...

2019-05-23 17:00 1789

China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province

TAIZHOU, China, May 22, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today the laun...

2019-05-22 23:20 6994

Scientists Identify New Therapeutic Target for Fatty Liver Disease

* Preclinical study highlights a novel therapy for the treatment of fatty liver disease, which affects up to 25% of the global population * Inhibiting interleukin 11 (IL11) signalling addresses multiple aspects of non-alcoholic steatohepatitis (NASH), including hepatic inflammation and fibros...

2019-05-22 18:24 1963

FDA Approves SORILUX(R) for Adolescent Plaque Psoriasis

ADELAIDE, Australia, May 22, 2019 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the US Food and Drug Administration (FDA) has approved SORILUX® (calcipotriene) Foam, 0.005% in adolescents. SORILUX is now approved for treating plaque psoriasis of the scalp and b...

2019-05-22 18:00 6573

Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea and DALLAS, May 20, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical-stage biotech company developing novel therapeutics for areas with high unmet medical needs, announced that the company presented interim data from a Phase I clinical study on BBT-877, a drug c...

2019-05-20 08:38 1817

ChemPartner and Berkeley Lights Take Next Step in B Cell Antibody Discovery Collaboration

SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 16, 2019 /PRNewswire/ -- Shanghai ChemPartner a leading global Contract Research Organization (CRO), along withBerkeley Lights, Inc. (BLI) , the leader in digital cell biology, announced ...

2019-05-16 23:00 1777

NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute

SYDNEY, May 15, 2019 /PRNewswire/ -- NeuClone Pharmaceuticals Ltd. (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it will initiate the Phase I clinical trial of its Stelara® (ustekinumab) biosimilar in t...

2019-05-15 20:13 1900

NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute

China Pharma Holdings, Inc. Reports First Quarter 2019 Financial Results

HAIKOU, China, May 15, 2019 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the quarter ...

2019-05-15 18:00 8360

China Biologic Reports Financial Results for the First Quarter of 2019

--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING, May 10, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"...

2019-05-11 04:30 9552

Kazia calls for greater awareness of the deadliest gynecological cancer in the US

SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal gynaecological cancer in the US. In 2019, around 22,530 women will receive a new d...

2019-05-08 20:00 6268

1 ... 109 110 111 112113